Vall d'Hebron University Hospital / Hospital Universitari Vall d'Hebron

Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study. (2022) Bettiol A, Urban ML, Bello F, Fiori D, Mattioli I, Lopalco G, Iannone F, et al. Journal article Duration of Ischemia Affects Outcomes Independent of Infarct Size in Stroke. (2022) Kim Y, Khose S, Zaidat OO, Hassan AE, Fifi JT, Nanda A, Atchie B, et al. Journal article Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis. (2022) Kerick M, Acosta-Herrera M, Pilar Simeon-Aznar C, Luis Callejas J, Assassi S, Proudman SM, Nikpour M, et al. Journal article Streptozotocin, 1982-2022: Forty Years from the FDA's Approval to Treat Pancreatic Neuroendocrine Tumors (2022) Capdevila J, Ducreux M, García Carbonero R, Grande E, Halfdanarson T, Pavel ME, Tafuto S, et al. Journal article, Review article The impact of COVID-19 on the management of neuroendocrine tumors (NETS): An international NET CONNECT survey of NET patients and healthcare professionals treating net patients (2022) Cives M, Hernando J, Lamarca A, Bouvier C, Caplin M, Pavel ME Journal article Discovering a new part of the phenotypic spectrum of Coffin-Siris syndrome in a fetal cohort (2022) van der Sluijs PJ, Joosten M, Alby C, Attié-Bitach T, Gilmore K, Dubourg C, Fradin M, et al. Journal article Loss-of-function variants in SRRM2 cause a neurodevelopmental disorder (2022) Cuinat S, Nizon M, Isidor B, Stegmann A, van Jaarsveld RH, van Gassen KL, van der Smagt JJ, et al. Journal article The CAR- Hematotox Identifies Patients at High Risk for Prolonged Neutropenia, Infectious Complications and Prolonged Hospitalization Following CD19-CART in R/R LBCL (2021) Rejeski K, Perez-Perez A, Iacoboni G, Penack O, Buecklein VL, Jentzsch L, Mougiakakos D, et al. Conference contribution IMMUNE PROFILING OF PATIENTS WITH ADVANCED SOLID TUMORS TREATED WITH INTRATUMORALLY ADMINISTERED CV8102 AS A SINGLE-AGENT OR IN COMBINATION WITH ANTI-PD-1 ANTIBODIES IN PHASE I CLINICAL TRIAL (2021) Codo P, Eigentler T, Heinzerling L, Krauss J, Weishaupt C, Ochsenreither S, Lebbe C, et al. Conference contribution Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results (2021) Pavel ME, Ćwikła JB, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Capdevila J, et al. Journal article